A 35-year-old male construction worker from Delhi presents with a 3-week history of productive cough, low-grade fever, and night sweats. Chest X-ray shows a cavitary lesion in the right upper lobe. Sputum smear microscopy is positive for acid-fast bacilli (AFB). He is started on anti-TB therapy under RNTCP. After 2 months of treatment, his sputum smear remains positive. Which of the following is the most likely reason for this treatment failure?

Explanation

## Treatment Failure in TB — RNTCP/NTEP Context ### Key Distinction: Sputum Positivity at 2 Months ≠ Treatment Failure **High-Yield:** Under RNTCP/NTEP guidelines, **treatment failure** is defined as sputum smear positivity at **5 months or later** during treatment. Sputum smear positivity at **2 months** is NOT classified as treatment failure — it is an indication to extend the intensive phase and investigate further, but it does not by itself confirm MDR-TB or drug resistance. This distinction is critical: the question asks about sputum positivity **after 2 months**, which is still within the intensive phase window. ### Most Common Cause at This Stage: Poor Adherence **Key Point:** Poor adherence to anti-TB drugs is the **single most common reason** for persistent smear positivity at 2 months in RNTCP settings, accounting for the majority of early bacteriological non-conversion in resource-limited settings (Park's Textbook of Preventive and Social Medicine). In this case: - Patient is on standard RNTCP regimen (2HRZE/4HR for drug-susceptible TB) - Sputum remains positive at 2 months — within the window where non-adherence is most impactful - **No prior TB history** mentioned — reducing prior probability of acquired MDR-TB - **No known MDR-TB contact** or healthcare worker exposure mentioned - Construction worker — irregular schedule, high mobility, known risk for poor adherence ### Why Not MDR-TB (Option A)? MDR-TB (resistance to isoniazid + rifampicin) is a serious concern but is **less likely as the primary cause** at 2 months in a new patient with no prior TB history and no documented MDR-TB risk factors. RNTCP guidelines recommend Drug Susceptibility Testing (DST) / CBNAAT (Xpert MTB/RIF) to confirm resistance before labeling a case as MDR-TB. Smear positivity at 2 months alone does not establish drug resistance. ### Why Not Options C or D? - **Option C (HIV-related malabsorption):** No HIV risk factors or HIV status mentioned; this is a less common cause and requires specific clinical context. - **Option D (Inadequate dosing):** The standard RNTCP regimen uses weight-based dosing and is well-validated; inadequate dosing in the standard regimen is not a recognized common cause of failure. ### RNTCP Management Algorithm for 2-Month Smear Positivity 1. Reinforce counselling and ensure strict DOT compliance 2. Assess barriers: cost, side effects, distance to clinic, pill count 3. Send sputum for CBNAAT/DST to rule out drug resistance 4. Extend intensive phase by 1 month if adherence is confirmed 5. Escalate to MDR-TB regimen only after DST confirmation **Clinical Pearl:** RNTCP mandates DOT (Directly Observed Therapy) for all patients. Sputum conversion by 2 months occurs in ~80% of adherent new smear-positive patients on standard therapy. Non-conversion at 2 months is the trigger to investigate adherence first, then drug resistance. *Reference: Park's Textbook of Preventive and Social Medicine, 26th edition; NTEP/RNTCP Technical and Operational Guidelines for TB Control in India.*